Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Similar articles for PubMed (Select 22888522)

1.

Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia.

Liang A, Zhang H, Fang Y, Li Y, Zhu D, Chen F, Lu H, Fu J, Bo L.

Pharmazie. 2012 Jul;67(7):635-8.

PMID:
22888522
2.
3.

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.

Gandhi V, Estey E, Keating MJ, Plunkett W.

J Clin Oncol. 1993 Jan;11(1):116-24.

PMID:
8418222
5.
6.

[Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].

Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.

Ai Zheng. 2003 Dec;22(12):1330-3. Chinese.

PMID:
14693062
7.

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.

Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ.

Leuk Lymphoma. 1993 Mar;9(4-5):343-50.

PMID:
8394169
8.

Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.

Sutoh H, Yamauchi T, Gotoh N, Sugiyama M, Ueda T.

Anticancer Res. 2003 Nov-Dec;23(6D):5037-42.

PMID:
14981964
9.

Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.

Kemena A, Gandhi V, Shewach DS, Keating M, Plunkett W.

Cancer Chemother Pharmacol. 1992;31(3):193-9.

PMID:
1464155
10.

The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.

Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF, Schaafsma MR, Westveer PH, Peters GJ, Noordhuis P, Muus P, Selleslag D, van der Holt B, Delforge M, Löwenberg B, Verhoef GE; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Blood. 2004 Apr 15;103(8):2908-13. Epub 2003 Dec 4. Erratum in: Blood. 2004 Jul 1;104(1):42.

12.

[High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].

Nowrousian MR, Seeber S, Miller AA, Anders C, Ohl S, Schmidt CG.

Onkologie. 1985 Feb;8(1):26-32. German.

PMID:
3885117
17.

High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.

Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.

Cancer Chemother Pharmacol. 2007 May;59(6):771-9. Epub 2007 Jan 26.

PMID:
17256136
18.

Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.

Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.

Cancer Res. 1987 Jun 1;47(11):3005-11.

19.
20.

Purine nucleoside analogues in the treatment of myleoid leukemias.

Robak T.

Leuk Lymphoma. 2003 Mar;44(3):391-409. Review.

PMID:
12688309
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk